Feelders, R. A. Et Al. 2023. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease. Frontiers in Endocrinology , vol.14 .

Feelders, R. A., Fleseriu, M., KADIOĞLU, P., Bex, M., González-Devia, D., Boguszewski, C. L., ... YAVUZ, D.(2023). Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease. Frontiers in Endocrinology , vol.14.

Feelders, Richard Et Al. "Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease," Frontiers in Endocrinology , vol.14, 2023

Feelders, Richard A. Et Al. "Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease." Frontiers in Endocrinology , vol.14, 2023

Feelders, R. A. Et Al. (2023) . "Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease." Frontiers in Endocrinology , vol.14.

@article{article, author={Richard A. Feelders Et Al. }, title={Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease}, journal={Frontiers in Endocrinology}, year=2023}